iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Short Interest Update

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) was the target of a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 108,461 shares, a growth of 382.5% from the June 15th total of 22,477 shares. Currently, 1.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 77,170 shares, the days-to-cover ratio is currently 1.4 days.

iShares Genomics Immunology and Healthcare ETF Trading Down 1.8%

Shares of IDNA opened at $32.95 on Tuesday. iShares Genomics Immunology and Healthcare ETF has a 12-month low of $20.93 and a 12-month high of $34.97. The stock has a market cap of $191.11 million, a P/E ratio of 14.76 and a beta of 0.92. The company has a 50-day moving average of $30.78 and a two-hundred day moving average of $29.66.

Institutional Investors Weigh In On iShares Genomics Immunology and Healthcare ETF

An institutional investor recently bought a new stake in iShares Genomics Immunology and Healthcare ETF stock. Triumph Capital Management purchased a new position in shares of iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,481 shares of the company’s stock, valued at approximately $35,000.

About iShares Genomics Immunology and Healthcare ETF

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.